| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514574000 | Polycarboxylic acid or salt thereof | 53 |
| 20100035994 | NOVEL HYDRATE FORM OF O-DESMETHYL VENLAFAXINE SUCCINATE - The present invention relates to a novel hydrate form of O-desmethyl venlafaxine succinate. The present invention further relates to processes for the preparation of the novel hydrate form, pharmaceutical compositions comprising it, second medical uses of the novel hydrate form, and methods using it for treating diseases such as generalised anxiety disorder, anxiety, depressive disorder, depression and panic disorder. | 02-11-2010 |
| 20100105776 | USE OF MALACHITE GREEN IN THE FORM OF DRUG FOR TREATING MALIGNANT NEOPLASMS - The use of malachite green in the form of a tetramethyldiamino-triphenyl-carbinol anhydro-oxalate [(C | 04-29-2010 |
| 20090306211 | Peritoneal dialysis fluid - The present invention concerns a peritoneal dialysis fluid with enhanced ultrafiltration during the dialysis dwell period. According to the present invention this is achieved by a peritoneal dialysis fluid comprising sodium ions, osmotic agent and a buffer, characterised in that it comprises citrate at a level of 4 to 10 mM in a final solution ready for use. | 12-10-2009 |
| 20090298946 | Local Anesthetic Deactivation - A chemical solution for deactivating the effects of local anesthetic is disclosed. Local anesthetic is important in many medical procedures, such as dentistry, surgical procedures, and veterinary medicine. In many cases, after the procedure has been completed, the need for blocking the nerve conductance is no longer needed or wanted, and the effects of local anesthesia can last for several hours post procedure. This invention works by two mechanisms, manipulating the pH and calcium concentration of the local cellular environment. The invention can be delivered via an oral transmucosal delivery device or via an injectable. It provides a safe and biologically acceptable means to quickly eliminate the effects of local anesthetic. The use of this invention will allow patients to quickly gain back their normal nerve function. | 12-03-2009 |
| 20090012174 | Compositions Having a High Antiviral and Antibacterial Efficacy - Antimicrobial compositions having a rapid antiviral and antibacterial effectiveness, and a persistent antiviral effectiveness, are disclosed. The antimicrobial compositions contain (a) a disinfecting alcohol, (b) an organic acid, (c) a buffering agent, and (d) water, wherein the composition has a pH of about 5 or less. | 01-08-2009 |
| 20080221213 | Tablets Comprising a High Load of Strontium - Tablets comprising strontium in the form of a strontium salt such as strontium malonate. The tablets are designed to contain a very high load of the strontium salt (75% w/w or more), which is especially advantageous due to the fact that strontium must be administered in relative high amounts for therapeutic use. Furthermore, the tablets provided by the present invention lead to an improved bioavailability and presents a therapeutic advantage. | 09-11-2008 |
| 20100113599 | AMPHIPATHIC CARBOXYLATES FOR THE TREATMENT OF IMMUNE-RELATED DISORDERS - The present invention relates to the use of at least one long-chain optionally-substituted amphipatic carboxylates (known as MEDICA drugs) or any salt, ester or amid thereof or any combination or mixture thereof, for the treatment and prevention of immune-related disorders, particularly, inflammatory conditions. More specifically, the invention relates to particular analogs of these MEDICA drugs, the 3,3,14,14 tetramethyl-hexadecanedioic acid (M16ββ), 4,4,15,15 tetramethyl-octadecanedioic acid (M18γγ) and 2,2,15,15-tetramethyl-hexadecanedioic acid (M16αα). The invention further provides methods, oral compositions and kits for the treatment and prevention of immune-related disorders using these MEDICA drugs. The disease is any one of multiple sclerosis, neurodegenerative disease, an atherosclerotic disease, inflammatory bowel diseases, arthritis. Wherein said atheroslerotic disease is any one of cardiovascular disease, cerebrovascular disease and peripheral vessel disease, and a malignant proliferative disorder line carcinoma, myeloma, leukemia, lymphoma, sarcoma and melanoma. | 05-06-2010 |
| 20100280123 | FOOD SUPPLEMENT CONTAINING ALPHA-KETO ACIDS FOR SUPPORTING DIABETES THERAPY - Food supplement containing alpha-keto acids for supporting diabetes therapy. The present invention relates to a formulation which is used as food supplement and contains alpha-keto acids for supporting therapy in diabetes mellitus type II (DM). | 11-04-2010 |
| 20090298945 | Aqueous Extracts from Monocotyledon Plants and Their Use in Cardioprotection - Method of treating hypertension with a trans-aconitic acid containing composition (e.g., a water extract derived from a monocotyledon plant). | 12-03-2009 |
| 20110207822 | COMPOSITIONS FOR CLEANING AND DISINFECTING NASAL TRACT AND SINUS CAVITY - Biodegradable compositions for cleaning and disinfecting nasal tract and sinus cavity using food additive ingredients or ingredients that are safe. | 08-25-2011 |
| 20080269337 | Method for the enhancing biocidal activity - A treatment for enhancing the activity of isothiazolinone compounds to control the growth of microbes in an aqueous system is disclosed, which comprises adding to said isothiazolinone compounds an amount of an alkylsulfosuccinate surfactant sufficient to improve efficacy of the isothiazolinone compound. Each alkyl group of the alkylsulfosuccinate contains at least 10 carbons. | 10-30-2008 |
| 20110269837 | PHOSPHORUS BINDER COMPOSITION FOR TREATMENT OF HYPERPHOSPHATEMIA - The present invention relates to oral pharmaceutical products which are useful for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of subjects. A method for binding phosphorus in ingesta and inhibiting its absorption from the gastrointestinal tract is also provided. The pharmaceutical products and methods of the present invention are particularly useful in the treatment of hyperphosphatemia of chronic uremia and reducing serum phosphorus levels in patients requiring such therapy. | 11-03-2011 |
| 20080319079 | Method for Administering Formoterol Using a Nebulizer - The present invention provides a method of administering formoterol, for example as a fumarate dihydrate, using a nebulizer device for the treatment of bronchoconstriction, such as that caused by asthma and chronic obstructive pulmonary disease. The method of this invention is particularly useful in pediatric, geriatric, handicapped and acutely ill individuals who have been denied the benefits of this medication due to the standard use of dry powder inhalers. The present invention addresses the difficulty of making available a viable commercial nebulizer solution for these individuals who cannot optimally use powder inhaler devices, which are the only presently available delivery systems for this medication. | 12-25-2008 |
| 20090099263 | Organ-adhesion preventing agent and process for preventing adhesion using thereof - There is disclosed an organ-adhesion preventing agent comprising a chemically-crosslinked γ-polyglutamic acid as an effective ingredient, as well as a process for preventing organ from adhesion comprising a step of bringing the adhesion-preventing agent into contact with or depositing the same onto the surface of a local organ and optionally the neighborhood thereof to be prevented from the post-operative adhesion. According to the present invention, there is provided an adhesion-preventing agent which is capable of effectively preventing the surfaces of organs from adhesion, and which can be absorbed in the body with high safety and be produced with ease and has high practical usefulness, as well as a process for preventing organ from adhesion by using the adhesion-preventing agent. | 04-16-2009 |
| 20090253798 | COLCHICINE SOLID COMPLEX; METHODS OF MAKING; AND METHODS OF USE THEREOF - Disclosed are new colchicine solid complexes, methods of making the solid complexes as well as formulations prepared therefrom and uses thereof. | 10-08-2009 |
| 20100160440 | INTRANASAL PHARMACEUTICAL COMPOSITIONS COMPRISING SUCCINIC ACID AND METHODS THEREOF - The present invention relates to intranasal pharmaceutical compositions for preventing and/or treating a disease selected from the group consisting of Alzheimer's disease, Parkinson's disease, cerebral ischemia and neurological damage due to stroke comprising a therapeutically effective amount of succinic acid or a pharmaceutically acceptable salt thereof, and a pharmaceutically and intranasally acceptable carrier. Further, the present invention relates to methods for preventing and/or treating a disease selected from the group consisting of Alzheimer's disease, Parkinson's disease, cerebral ischemia and neurological damage due to stroke with using compositions of the present invention. | 06-24-2010 |
| 20080214670 | Therapeutic Malonic Acid/Acetic Acid C60 Tri-Adducts of Buckminsterfullerene and Methods Related Thereto - Disclosed and claimed herein are e,e,e malonic acid/acetic acid tri-adduct of buckminsterfullerene of the general formula C | 09-04-2008 |
| 20110112196 | NRF2 SCREENING ASSAYS AND RELATED METHODS AND COMPOSITIONS - Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death. | 05-12-2011 |
| 20100069498 | USE OF ALPHA-KETOGLUTARIC ACID FOR THE TREATMENT OF HIGH PLASMA GLUCOSE CONDITION - A method for improving adsorption of amino acids in a vertebrate, including mammal and bird, is included. The method comprises administering to a vertebrate, including mammal and bird, in a sufficient amount and/or at a sufficient rate to enable a desired effect, AKG, AKG derivates or metabolites, AKG analogues or mixtures thereof. Also contemplated is a method for decreasing adsorption of glucose in a vertebrate, including mammal and bird, comprising administering to the vertebrate, including mammal and bird, in the need thereof, AKG, AKG derivates or metabolites, AKG analogues or mixtures thereof, for decreasing glucose adsorption as well as compositions for use in treatment. | 03-18-2010 |
| 20090111878 | Teeth Whitening Material and Teeth Whitening Method - The present invention relates to a tooth bleaching material containing peroxyglutaric acid and/or peroxypolyacrylic acid as a bleaching ingredient, as well as a method of bleaching teeth which include the step of applying the tooth bleaching material in the form of a dilute solution or without dilution onto surfaces of discolored teeth. In accordance with the present invention, there are provided a tooth bleaching material for bleaching and removing colored sediments (colored or discolored deposits) on teeth which do not essentially require irradiation with light, and is readily used with a high safety and further suitable as a domestic bleaching material, as well as a tooth bleaching method using the above tooth bleaching material. | 04-30-2009 |
| 20090069429 | Compositions Comprising Alpha-Ketoglutarate and Their Use for Modulating Muscle Performance - This invention relates to a composition comprising Alpha-ketoglutarate (AKG) for modulating muscle performance in a mammal including a human being. Also contemplated is a method for modulating muscle performance in a vertebrate, including mammal and bird, and the manufacture of a composition for the prevention, alleviation or treatment of muscle performance in said vertebrate. | 03-12-2009 |
| 20110130462 | Aqueous Organic Acidic Solution for Sterilization and Microbial Growth Inhibition - The present invention consists of a two acid core aqueous acidic solution with a pH value of less than one that is nonreactive to human skin, can be safely ingested, and is effective as both a disinfectant and a microbial growth inhibition agent. The solution consists of hydrochloric acid admixed aqueous citric acid. The present invention further comprises a method of disinfecting food products and related surfaces during processing, preparation, and transport. | 06-02-2011 |
| 20110118355 | TREATMENT OF MIGRAINE HEADACHES USING ANTIESTROGENS - A method of preventing or reducing the frequency of the occurrence of migraine headaches in a patient who is a previous sufferer of migraine headaches, especially accompanied by prodrome and/or aura, comprises administering an effective amount therefor of an antiestrogen to the patient for a period of time and sufficiently far in advance of the occurrence of a migraine headache to prevent the development of the prodromal phase and/or aura phase of the migraine headache. | 05-19-2011 |
| 20110213036 | COMPOSITION FOR PREVENTION OF TOOTH HYPERSENSITIVITY - The present invention relates to a composition for prevention of tooth hypersensitivity, and more particularly to a composition for prevention of tooth hypersensitivity, which comprises an adhesive polymer for coating teeth, an active ingredient for prevention of hypersensitivity, a substance for promoting the penetration of the active ingredient for prevention of hypersensitivity, a desensitizing active ingredient, and a pH-adjusting agent. The composition for prevention of tooth hypersensitivity according to the invention can rapidly show the effect of preventing tooth hypersensitivity while maintaining the sensory feel of conventional tooth desensitizers, and it can maintain the tooth hypersensitivity-preventing effect for a long time. | 09-01-2011 |
| 20100004338 | TOPICAL GEL COMPOSITION COMPRISING AZELAIC ACID - The present invention discloses a novel azelaic acid topical pharmaceutical gel composition that does not contain lecithin and a process for its preparation. | 01-07-2010 |
| 20090312427 | Medicament for Use in Connection With Cartilage Impairment - Use of a substance for treating medical joint conditions, e.g. arthrosis, rheumatoid arthritis and cartilage impairment. The use includes the use of alpha-ketoglutaric acid, glutamine or glutamic acid, as well as salts, amides, di- or tripeptides of the mentioned substances. | 12-17-2009 |
| 20110251282 | LIQUID COMPOSITIONS OF CALCIUM ACETATE - The invention relates to an aqueous liquid composition of calcium acetate, sweetener, and taste masking agent. Also provided is a method for binding phosphorus within the gastrointestinal tract of an individual by administering to the individual an aqueous solution of at least calcium acetate. | 10-13-2011 |
| 20110060048 | Removing alcohol in vivo through esterification - The present invention is pertaining to a method to chemically remove ethanol in the stomach before a significant amount of ethanol enters the blood stream. The key chemical reaction responsible for ethanol removal is esterification through a reaction between ethanol and acetic acid. Ethanol reacts with acetic acid to produce water and ethyl acetate, which is a harmless ester found in many food products. In theory, if an intoxicated individual consumes a molar quantity of vinegar similar to the amount of ethanol in the alcoholic beverage, much of the ethanol will be converted into harmless products. Low cost, practical methods for alcohol drinkers to orally take a sufficient amount of acetic components are invented. These methods include drinks containing a mixture of acetic acid and potassium hydroxide with an appropriate level of acidity. | 03-10-2011 |
| 20110039935 | USE OF PHARMACOLOGICALLY ACTIVE CHEMICAL COMPOUNDS - The present invention relates to the new use of alpha-ketoglutarate, amides, and salts and mixtures thereof for the manufacture of a pharmaceutical preparation or a food or feed supplement for the in vivo therapeutic improvement of blood vessel elasticity, in particular arterial elasticity in a subject in need thereof. Improving the blood vessel elasticity may be used in the for the treatment and/or prophylaxis of hypertension, pulmonary arterial hypertension, cardiovascular disease, retinal vascular disease, heart failure, atherosclerosis, ventricular hypertrophy, stroke, arterial aneurysm, kidney failure, nephrosclerosis and diseases related to hypertension. | 02-17-2011 |
| 20080249178 | MAGNESIUM COMPOSITIONS AND USES THEREOF FOR INCREASING LIFESPAN - A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided. | 10-09-2008 |
| 20080293815 | HCA FOR IMPROVED HDL SERUM LIPIDS PROFILE - Described herein are compositions and methods for increasing serum high-density cholesterol lipoprotein (HDL) levels in an individual in need thereof comprising orally administering an effective amount of HCA. | 11-27-2008 |
| 20090088476 | Dental irrigant - An irrigant comprising either a hypochlorite compound or a chlorhexidine compound in combination with at least one surfactant and preferably two or more surfactants, including fluorosurfactants, ethoxylates, sulfonates, quaternary ammonium compounds, amine oxides, and combinations thereof, wherein each of the surfactants are capable of complexing with one another. | 04-02-2009 |
| 20120302642 | Viscous Acidic Abrasive Cleaning Compositions - Aqueous acidic, abrasive hard surface cleaning composition comprising: about 0.5-3.5% wt. of a thickener system which includes both a colloid forming clay, preferably a montmorillonite clay, and a gum based thickener, preferably xantham gum; about 0.01-2.5% wt. of a surfactant selected from anionic surfactants, nonionic surfactants, and mixtures thereof; an antimicrobially effective amount of at least one organic acid present in an amount of from about 2-12% wt.; as an abrasive constituent, pumice, which may be present in an amount of at least about 5% wt.; optionally but preferably an opacifying/tinting constituent; 0-5% wt. of one or more optional constituents for improving the aesthetic characteristics of the compositions; and, at least 75% wt. of water; wherein the compositions exhibit a viscosity of between about 250 cps to about 1000 cps at 25° C., and, exhibit an acidic pH of less than about 5. The compositions are particularly useful in the cleaning treatment of hard surfaces, particularly lavatory surfaces. | 11-29-2012 |
| 20100016438 | Granulated crystal compilation composed of pure organic minerals used in all food applications resulting in energy supplementation, diet and weight regulation, and medicinal effects - A composition made of pure natural minerals that can be used in all food applications resulting in energy supplementation, diet and weight regulation, and medicinal benefits. | 01-21-2010 |
| 20100137444 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES - The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents. | 06-03-2010 |
| 20080255237 | Pesticidal Composition - A pesticidal preparation comprises a pesticidal composition consisting essentially of a mixture of garlic oil and allyl isothiocyanates (AITCs) in the weight ratio of from 95:5 to 60:40. It is especially effective as a pesticide, especially against nematodes commonly found in the soil. | 10-16-2008 |
| 20110065798 | ANTI-INFECTIVE LUBRICANT FOR MEDICAL DEVICES AND METHODS FOR PREPARING THE SAME - A lubricious antiseptic coating material containing various solvents to achieve mutual miscibility and provide a generally homogenous product. A coating material is provided having an antipathogenic agent and a solvent for dissolving the same. The coating further includes a lubricious agent and a solvent for dissolving the same. Thus, the coating material contains antiseptic and lubricious properties suitable for application to a desired surface to kill or inhibit the growth of pathogens known to cause catheter related bloodstream infections. | 03-17-2011 |
| 20120178815 | Compositions of (-)-E-10-OH-NT and Methods for Their Synthesis and Use - This present disclosure provides compositions comprising E-10-OH-NT metabolites of AT and NT, methods for their synthesis and methods for their use. | 07-12-2012 |
| 20120208888 | Biocide compositions and related methods - The invention relates to biocide compositions comprising organic acyl polyoxychlorine and methods for producing said biocide compositions. The biocide compositions form reactive oxygen species when contacted by microorganisms, proteinaceous substances, and oxidizable organic based contaminants. | 08-16-2012 |
| 20120065269 | System for Reducing Bacteria on Unprocessed Food Surfaces While Extending Shelf Life - A system for substantially reducing surface contaminants of a food substance comprising a substantially transparent and odorless solution made from a plurality of substantially organic compounds selected from: citric acid, sodium citrate, vegetable glycerin, sea salt, potassium sorbate, decyl glucoside, calcium ascorbate, grapefruit seed extract, and sodium bisulfite, and an applicator for applying the solution to the food substance. The solution ratio of organic compounds is approximately: 2% citric acid, 2% sodium citrate, 0.2% vegetable glycerin, 0.2% potassium sorbate; 0% to 0.4% decyl glucoside, 0% to 0.2% calcium ascorbate, 0% to 0.2% grapefruit seed extract, 0% to 0.1% sodium bisulfite, and 0.2% to 2% sea salt. | 03-15-2012 |
| 20120016032 | Cosmetic Composition Containing Calcium Citrate And N-Acylated Aminoalcohol Derivative To Prevent Dry Skin And Signs Of Cutaneous Ageing - Cosmetic compositions comprising calcium citrate and at least one N-acylated aminoalcohol according to formula (I). | 01-19-2012 |
| 20120309834 | NOVEL USES OF ADIPIC ACID - The present invention relates to a method for preventing or treating obesity, diabetes, dyslipidemia, fatty liver or insulin resistance syndrome, comprising: administering to a mammalian subject in need thereof a therapeutically effective amount of a composition comprising adipic acid. The present composition containing adipic acid as an active ingredient is very effective in preventing or treating obesity, diabetes, dyslipidemia, fatty liver (preferably, non-alcoholic fatty liver) or insulin resistance syndrome. The composition of the present invention useful as pharmaceuticals compositions or functional food compositions has therapeutic efficacies for obesity, dyslipidemia or fatty liver, and also induces significant decrease in fasting glucose level and blood insulin level to improve type 2 diabetes, insulin resistance and related metabolic diseases. | 12-06-2012 |
| 20110105617 | METHOD FOR TREATMENT OF NEOPLASTIC DISEASES WITH ALPHA-KETO GLUTARATE AND/OR SALTS THEREOF - A method for treatment or prophylaxis of neoplastic diseases includes administering an antineoplastic preparation to a subject in need thereof. The active component of the antineoplastic preparation is alpha-ketoglutarate and/or a salt of alpha-ketoglutarate. | 05-05-2011 |
| 20110184067 | O-DESMETHYLVENLAFAXINE SUCCINATE POLYMORPH & PROCESS FOR PREPARING THEREOF - This disclosure relates to a crystalline form of O-desmethylvenlafaxine and a process for its preparation. The disclosed crystalline form of O-desmethylvenlafaxine can be used for the manufacture of pharmaceutical compositions for the treatment of depression. | 07-28-2011 |
| 20120165411 | Method for Treating Pancreatitis - Gemcabene, a carboxyalkylether, is effective in the treatment and prevention of pancreatitis in subjects. The compound can be administered in an effective dose as the free acid, a pharmaceutically acceptable salt, or an ester or pro-drug that is hydrolyzed or otherwise metabolized in situ to gemcabene as the free acid or salt thereof. | 06-28-2012 |
| 20120083531 | CALCIUM CITRATE AND CALCIUM LACTATE FORMULATIONS FOR ALTERATION OF BIOPHYSICAL PROPERTIES OF MUCOSAL LINING - The present invention relates to pharmaceutical compositions suitable for inhalation, comprising as an active ingredient calcium lactate or calcium citrate. The invention also relates to methods of treating, preventing, and reducing the spread of an infection of the respiratory tract, comprising administering a pharmaceutical composition that comprises calcium lactate or calcium citrate as an active ingredient. | 04-05-2012 |
| 20100273885 | LOW ENVIRONMENTAL IMPACT PESTICIDE MADE FROM "GRAS" INGREDIENTS FOR USE AGAINST COQUI FROGS AND OTHER SPECIES - The current invention involves compositions and methods for killing various soft-bodied animals of interest (more specifically, Coqui frogs and Coqui frog eggs are targeted) with a low pH adjusted pesticide. The method involves contacting the soft-bodied animal of interest with the low pH adjusted pesticide, wherein the pesticide is a propionic acid composition, a citric acid composition, an Acidic Calcium Sulfate (ACS) composition, or combination thereof. The preferred pesticide composition has a working concentration that is less than about 15% (w/v), and a pH less than about pH 2.5, which has a lethal effect on Coqui frogs, but is less phytotoxic than higher concentration pesticides. The method includes spraying any of the pH adjusted pesticides thoroughly an area inhabited by the soft-bodied animals of interest, which includes the under brush, under bushes, and typically any hiding places. On a large scale, the method contemplates filling various types of industrial spraying equipment with the pesticide and saturating entire pest inhabited areas. | 10-28-2010 |
| 20100273884 | METHOD FOR STABLE AND CONTROLLED DELIVERY OF (-)-HYDROXYCITRIC ACID - The present invention provides stable encapsulated (−)-hydroxycitric acid (“HCA”)-containing compositions and methods of making the same. A method is provided by which the hygroscopic salts of HCA in their relatively pure and active forms, including especially the potassium salt, but also including the sodium salt, are rendered non-hygroscopic and stable (that is, not prone to lactonization, not readily subject to attachment to ligands which inhibit absorption or lead to excretion, and so forth) such that these HCA salts might be included in dry delivery formats, liquid delivery and in controlled-release vehicles. The nonhygroscopic salts of HCA and its derivatives likewise may be protected against acid degradation, lactonization and undesirable ligand binding when exposed to acidic environments or other challenging conditions. The method taught herein can be employed to reduce the polar/ionic qualities of HCA salts and derivatives when presented to the intestinal lumen to provide advantages in absorption. | 10-28-2010 |
| 20120252898 | METHOD OF PRODUCING A STABILIZED NATURALLY OCCURING HYDROXYCITRIC ACID (HCA) FROM GARCINIA INDICA FRUIT - A method of producing a stabilized naturally occurring hydroxycitric acid is provided. In one embodiment, the method comprises combining an aqueous liquid with | 10-04-2012 |
| 20090018199 | Methods of Administering 3, 3, 14, 14 Tetramethyl Hexadecane 1, 16 Dioic Acid - The present invention provides methods for lowering LDL, VLDL, total cholesterol, triglycerides, Insulin resistance and hypertension, and methods for elevating HDL in subjects in need thereof. Additionally, the present invention provides methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid for the above indications. | 01-15-2009 |
| 20110003896 | DIMERIC DOUBLE METAL SALTS OF (-)-HYDROXYCITRIC ACID, METHODS OF MAKING AND USES OF SAME - The present invention relates to soluble dimeric double metal salt compositions of (−)-hydroxycitric acid (“HCA”), as well as methods for making and using the same. The invention provides dimeric double metal salts of group IA and IIA of HCA (hereinafter, “DDM-HCAs”). The present invention provides methods to make DDM-HCAs of the invention which can be employed to alter the polar/ionic qualities of HCA salts and derivatives to improve solubility of HCA compositions. DDM-HCAs of the invention are soluble HCA-containing compositions useful as dietary supplements and suitable for manipulations under those conditions necessary for tabletting, encapsulation, and the production of dry powders, particularly for use as a beverage premix. Methods of use of the composition include treatment for suppression of appetite, for weight loss, for an increase in the rate of fat metabolism, for reduction in blood lipids and postprandial lipemia, and to increase the plasma level of (−)-hydroxycitric acid. | 01-06-2011 |
| 20120329876 | METHOD AND COMPOSITION FOR STABLE AND CONTROLLED DELIVERY OF (-)-HYDROXYCITRIC ACID - The present invention provides stable encapsulated (−)-hydroxycitric acid (“HCA”)-containing compositions and methods of making the same. A method is provided by which the hygroscopic salts of HCA in their relatively pure and active forms, including especially the potassium salt, but also including the sodium salt, are rendered non-hygroscopic and stable (that is, not prone to lactonization, not readily subject to attachment to ligands which inhibit absorption or lead to excretion, and so forth) such that these HCA salts might be included in dry delivery formats, liquid delivery and in controlled-release vehicles. The nonhygroscopic salts of HCA and its derivatives likewise may be protected against acid degradation, lactonization and undesirable ligand binding when exposed to acidic environments or other challenging conditions. The method taught herein can be employed to reduce the polar/ionic qualities of HCA salts and derivatives when presented to the intestinal lumen to provide advantages in absorption. | 12-27-2012 |
| 20130018102 | NUTRITIONAL SUPPLEMENT FOR THE ENHANCEMENT OF MUSCLE PERFORMANCE AND RECOVERY - Described herein are nutritional supplements containing α-hydroxy-isocaproic acid and aspartic acid (e.g., DAA) and their methods of use in enhancing muscle performance and/or recovery after exercise. The nutritional supplements can be used to enhance muscle building and lean body mass, enhance muscle and physical performance, enhance recovery, and prevent catabolism (muscle atrophy or wasting) when administered to a mammalian subject. | 01-17-2013 |
